Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

(2015) William H. Chappell et al.   Oncotarget

Paradoxical Aspects of Rapamycin Immunobiology in Transplantation

(2011) I. R. Ferrer et al.   AMERICAN JOURNAL OF TRANSPLANTATION

The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors

(2011) Anne Dormond-Meuwly et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055: Figure 1

(2011) Gayle Marshall et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma

(2011) Didier Roulin et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Understanding the benefit of metformin use in cancer treatment

(2011) Ryan JO Dowling et al.   BMC Medicine

Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice

(2011) J M García-Martínez et al.   BRITISH JOURNAL OF CANCER

Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1

(2011) I. Ben Sahra et al.   CANCER RESEARCH

Reduced VEGF Production, Angiogenesis, and Vascular Regrowth Contribute to the Antitumor Properties of Dual mTORC1/mTORC2 Inhibitors

(2011) B. L. Falcon et al.   CANCER RESEARCH

Activation of mTORC2 by Association with the Ribosome

(2011) Vittoria Zinzalla et al.   CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors

(2011) Arkaitz Carracedo et al.   CELL CYCLE

Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma

(2011) C. Santiskulvong et al.   CLINICAL CANCER RESEARCH

Current and future directions in mammalian target of rapamycin inhibitors development

(2011) Angelica Fasolo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Evidence for Direct Activation of mTORC2 Kinase Activity by Phosphatidylinositol 3,4,5-Trisphosphate

(2011) Xiaoqing Gan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting the JNK Signaling Pathway Potentiates the Antiproliferative Efficacy of Rapamycin in LS174T Colon Cancer Cells

(2011) Michael Benoit et al.   JOURNAL OF SURGICAL RESEARCH

Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors

(2011) E. Vilar et al.   MOLECULAR CANCER THERAPEUTICS

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mammalian target of rapamycin as a target in hematological malignancies

(2011) Kevin R. Kelly et al.   Targeted Oncology

Switch to a Sirolimus-Based Immunosuppression in Long-Term Renal Transplant Recipients: Reduced Rate of (Pre-)Malignancies and Nonmelanoma Skin Cancer in a Prospective, Randomized, Assessor-Blinded, Controlled Clinical Trial

(2010) R. Salgo et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment

(2010) Carlos García-Echeverría   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy

(2010) Xuerong Wang et al.   CANCER BIOLOGY & THERAPY

Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2

(2010) K. Yu et al.   CANCER RESEARCH

Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia

(2010) F. Chiarini et al.   CANCER RESEARCH

Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids

(2010) Yasemin Sancak et al.   CELL

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

(2010) N. Chapuis et al.   CLINICAL CANCER RESEARCH

A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer

(2010) A. J. Armstrong et al.   CLINICAL CANCER RESEARCH

The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma

(2010) D. C. Cho et al.   CLINICAL CANCER RESEARCH

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer

(2010) Sébastien Albert et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The mTOR Kinase Determines Effector versus Memory CD8 + T Cell Fate by Regulating the Expression of Transcription Factors T-bet and Eomesodermin

(2010) Rajesh R. Rao et al.   IMMUNITY

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies

(2010) N Chapuis et al.   LEUKEMIA

Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo

(2010) Didier Roulin et al.   Molecular Cancer

Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway byNanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma

(2010) Diana Cirstea et al.   MOLECULAR CANCER THERAPEUTICS

Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?

(2010) I. Ben Sahra et al.   MOLECULAR CANCER THERAPEUTICS

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

(2010) Matthew R Janes et al.   NATURE MEDICINE

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets

(2010) Charles Swanton et al.   Genome Medicine

The Multifunctional Role of mTOR in Innate Immunity: Implications for Transplant Immunity

(2009) M. D. Säemann et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001

(2009) Philipp Baumann et al.   ANTI-CANCER DRUGS

Rapamycin inhibits mTORC1, but not completely

(2009) Carson C. Thoreen et al.   Autophagy

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

(2009) Juan M. García-Martínez et al.   BIOCHEMICAL JOURNAL

Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia

(2009) A. M. Roccaro et al.   BLOOD

The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas

(2009) K Shoji et al.   BRITISH JOURNAL OF CANCER

mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice

(2009) David A. Guertin et al.   CANCER CELL

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

(2009) C. M. Chresta et al.   CANCER RESEARCH

Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels

(2009) D. Mahalingam et al.   CLINICAL CANCER RESEARCH

A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia

(2009) A. E. Perl et al.   CLINICAL CANCER RESEARCH

Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway

(2009) Todd Morgan et al.   CURRENT CANCER DRUG TARGETS

mTOR and cancer: many loops in one pathway

(2009) Alejo Efeyan et al.   CURRENT OPINION IN CELL BIOLOGY

Combined inhibition of Dnmt and mTOR signaling inhibits formation and growth of colorectal cancer

(2009) Yan-Jie Zhang et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway

(2009) Edoardo Missiaglia et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

(2009) Sherif S. Farag et al.   LEUKEMIA RESEARCH

Enhancing CD8 T-cell memory by modulating fatty acid metabolism

(2009) Erika L. Pearce et al.   NATURE

mTOR regulates memory CD8 T-cell differentiation

(2009) Koichi Araki et al.   NATURE

Molecular mechanisms of mTOR-mediated translational control

(2009) Xiaoju Max Ma et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

(2009) Saskia M. Brachmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

New Insights into mTOR Signaling: mTORC2 and Beyond

(2009) D. R. Alessi et al.   Science Signaling

The Role of mTOR Inhibitors in the Management of Posttransplant Malignancy

(2009) Anthony P. Monaco   TRANSPLANTATION

Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial

(2009) Francesco P. Schena et al.   TRANSPLANTATION

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY

Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models

(2009) Nancy Lee et al.   BMC Pharmacology & Toxicology

mTOR, Cancer and Transplantation

(2008) Edward K. Geissler et al.   AMERICAN JOURNAL OF TRANSPLANTATION

A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL

(2008) Thomas Decker et al.   ANNALS OF HEMATOLOGY

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

(2008) V. Serra et al.   CANCER RESEARCH

Overexpression of Vascular Endothelial Growth Factor and the Development of Post-Transplantation Cancer

(2008) A. Basu et al.   CANCER RESEARCH

Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular Carcinoma

(2008) Z. Wang et al.   CLINICAL CANCER RESEARCH

Pilot Study of Rapamycin in Patients with Hormone-Refractory Prostate Cancer

(2008) Robert J. Amato et al.   Clinical Genitourinary Cancer

Oncogenic MAPK Signaling Stimulates mTORC1 Activity by Promoting RSK-Mediated Raptor Phosphorylation

(2008) Audrey Carrière et al.   CURRENT BIOLOGY

mTOR inhibitors in the treatment of cancer

(2008) Angelica Fasolo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Hypoxia regulates TSC1/2 mTOR signaling and tumor suppression through REDD1-mediated 14 3 3 shuttling

(2008) M. P. DeYoung et al.   GENES & DEVELOPMENT

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

(2008) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

The cancer biomarker problem

(2008) Charles L. Sawyers   NATURE

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE

The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1

(2008) Y. Sancak et al.   SCIENCE

Changes in the Immune Responses Against Human Herpesvirus-8 in the Disease Course of Posttransplant Kaposi Sarcoma

(2008) Patrizia Barozzi et al.   TRANSPLANTATION

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

(2008) Tim F Cloughesy et al.   PLOS MEDICINE